Bristol Trial Shows Anti‑Inflammatory Drug Helps Mood
SkimNews Take
The trial's success with an anti-inflammatory drug for treatment-resistant depression suggests a potential paradigm shift, where a subset of mental health conditions may be treatable by addressing systemic physiological imbalances rather than solely neurological ones.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Bristol led a randomized controlled trial testing tocilizumab for treatment‑resistant depression, published in JAMA Psychiatry on May 20.
- Tocilizumab, an IL‑6 inhibitor, was given to 14 of 30 participants with moderate‑to‑severe depression and low‑grade inflammation, while 16 received a saline placebo.
- Trial four‑week follow‑up showed the tocilizumab group experienced reduced depression severity, anxiety, and fatigue and reported higher quality‑of‑life scores versus placebo, though the small sample limited statistical significance.
- University of Cambridge and Cambridgeshire and Peterborough NHS Foundation Trust recruited the 30 participants with moderate-to-severe depression and low‑grade inflammation.
- Study notes that about one‑third of depressed patients exhibit elevated inflammatory markers, suggesting immune‑based therapies could help those unresponsive to conventional antidepressants.
Why it matters: Patients with treatment‑resistant depression, about one‑third of all depressed individuals, gain a new therapeutic option as 14 of 30 trial participants receiving tocilizumab reported lower depression, anxiety and fatigue scores, improving quality of life.
